tiprankstipranks
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
US Market

Karyopharm Therapeutics (KPTI) Income Statement

Compare
1,162 Followers

Karyopharm Therapeutics Income Statement

Last quarter (Q3 2024), Karyopharm Therapeutics's total revenue was $38.78M, an increase of 7.70% from the same quarter last year. In Q3, Karyopharm Therapeutics's net income was $-32.07M. See Karyopharm Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 146.03M$ 157.07M$ 209.82M$ 108.08M$ 40.89M
Gross Profit
$ 141.09M$ 151.86M$ 206.42M$ 105.38M$ 38.49M
Operating Expenses
$ 270.63M$ 294.06M$ 304.69M$ 277.23M$ 227.76M
Depreciation and Amortization
$ 530.00K$ 621.00K$ 789.00K$ 972.00K$ 974.00K
EBITDA
$ -118.42M$ -139.31M$ -96.98M$ -167.85M$ -182.93M
Operating Income
$ -129.54M$ -142.20M$ -98.27M$ -171.85M$ -189.28M
Other Income/Expenses
$ -13.24M$ -22.72M$ -25.55M$ -24.11M$ -10.28M
Pretax Income
$ -142.78M$ -164.92M$ -123.82M$ -195.96M$ -199.55M
Net Income
$ -143.10M$ -165.29M$ -124.09M$ -196.27M$ -199.59M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -1.25$ -2.02$ -1.65$ -2.72$ -3.22
Diluted EPS
$ -1.25$ -2.02$ -1.65$ -2.72$ -3.22
Weighted Average Shares Outstanding
114.22M 81.87M 75.22M 72.04M 61.96M
Weighted Average Shares Outstanding (Diluted)
114.22M 81.87M 75.22M 72.04M 61.96M
Currency in USD

Karyopharm Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis